Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Fuji
Daiichi Sankyo
US Army
Cerilliant
Chubb
Argus Health
Harvard Business School
Merck
Fish and Richardson
UBS

Generated: August 21, 2017

DrugPatentWatch Database Preview

Astellas Company Profile

« Back to Dashboard

What is the competitive landscape for ASTELLAS, and what generic alternatives to ASTELLAS drugs are available?

ASTELLAS has thirty-one approved drugs.

There are thirty US patents protecting ASTELLAS drugs on ASTELLAS drugs in the past three years.

There are three hundred and seventy-four patent family members on ASTELLAS drugs in forty-two countries.

Summary for Applicant: Astellas

Patents:30
Tradenames:17
Ingredients:13
NDAs:31
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astellas
CEFIZOX
ceftizoxime sodium
INJECTABLE;INJECTION050560-001Sep 15, 1983DISCNNoNo► Subscribe► Subscribe► Subscribe
Astellas
ARISTOCORT
triamcinolone acetonide
OINTMENT;TOPICAL080750-004Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Astellas
CRESEMBA
isavuconazonium sulfate
POWDER;IV (INFUSION)207501-001Mar 6, 2015RXYesYes► Subscribe► Subscribe► Subscribe
Astellas
CYCLOCORT
amcinonide
CREAM;TOPICAL018116-002Approved Prior to Jan 1, 1982DISCNYesNo► Subscribe► Subscribe► Subscribe
Astellas
CYCLOCORT
amcinonide
LOTION;TOPICAL019729-001Jun 13, 1988DISCNYesNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Astellas

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Astellas
MYCAMINE
micafungin sodium
INJECTABLE;IV (INFUSION)021506-003Jun 27, 2006► Subscribe► Subscribe
Astellas
ADENOSCAN
adenosine
SOLUTION;IV (INFUSION)020059-001May 18, 1995► Subscribe► Subscribe
Astellas
MYCAMINE
micafungin sodium
INJECTABLE;IV (INFUSION)021506-002Mar 16, 2005► Subscribe► Subscribe
Astellas
PROGRAF
tacrolimus
INJECTABLE;INJECTION050709-001Apr 8, 1994► Subscribe► Subscribe
Astellas
ADENOSCAN
adenosine
SOLUTION;IV (INFUSION)020059-001May 18, 1995► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for ASTELLAS drugs

Drugname Dosage Strength Tradename Submissiondate
enzalutamide
Capsules40 mg
XTANDI
8/31/2016
micafungin sodium
For Injection50 mg/vial and 100 mg/vial
MYCAMINE
6/16/2014
tacrolimus
Extended-release Capsules0.5 mg, 1 mg, and 5 mg
ASTAGRAF XL
11/15/2013
regadenoson
Injection0.08 mg/mL, 5 mL vial
LEXISCAN
4/10/2012
solifenacin succinate
Tablets5 mg and 10 mg
VESICARE
4/8/2009
adenosine
Injection3 mg/mL, 20 mL and 30 mL vials
ADENOSCAN
4/18/2005
adenosine
Injection3 mg/mL, 20 mL and 30 mL vials
ADENOSCAN
4/16/2005

Non-Orange Book Patents for Astellas

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,956,179Process for preparing an A2A-adenosine receptor agonist and its polymorphs► Subscribe
7,112,565Stabilized pharmaceutical composition in lyophilized form► Subscribe
7,151,182Intermediates for N-substituted carbamoyloxyalkyl-azolium derivatives► Subscribe
8,648,105Diarylthiohydantoin compounds► Subscribe
6,770,290 Amphotericin B liposome preparation► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Astellas Drugs

Country Document Number Estimated Expiration
New Zealand298144► Subscribe
Japan2016183200► Subscribe
Hungary229089► Subscribe
World Intellectual Property Organization (WIPO)2007127010► Subscribe
Russian Federation2449993► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Astellas Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
90003-2.LSweden► SubscribePRODUCT NAME: REGADENOSON OCH SALTER DAERAV; REG. NO/DATE: EU/1/10/643/001 20100906
C0096France► SubscribePRODUCT NAME: ISAVUCONAZOLE; REGISTRATION NO/DATE: EU/1/15/1036 20151015
90060-0Sweden► SubscribePRODUCT NAME: ENZALUTAMID OCH FARMACEUTISKT ACCEPTABLA SALTER DAERAV; REG. NO/DATE: EU/1/13/846 20130621
2014000122Germany► SubscribePRODUCT NAME: SITAGLIPTIN IN ALLEN DEM SCHUTZ DES GRUNDPATENTS UNTERLIEGENDEN FORMEN; REGISTRATION NO/DATE: EU/1/07/383/001-018 20070321
C0071France► SubscribePRODUCT NAME: ENZALUTAMIDE OU SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/13/846 20130625
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

UBS
McKesson
Federal Trade Commission
AstraZeneca
Cerilliant
Farmers Insurance
Baxter
Chinese Patent Office
Julphar
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot